Crossmark

Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial

Crossref DOI link: https://doi.org/10.1038/s41467-025-60757-7

Published Online: 2025-07-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hsiehchen, David https://orcid.org/0000-0001-9139-302X
Kainthla, Radhika

Kline, Heather

Siglinsky, Ellen

Ahn, Chul

Zhu, Hao https://orcid.org/0000-0002-8417-9698
Funding

Funding for this research was provided by:

Cancer Prevention and Research Institute of Texas
License Information

Text and Data Mining valid from 2025-07-01

Version of Record valid from 2025-07-01
More Information

Article History

Received: 3 January 2025

Accepted: 3 June 2025

First Online: 1 July 2025

Competing interests

: D.H. has served as a consultant for AztraZeneca. H.Z. is a co-founder of Quotient Therapeutics and Jumble Therapeutics, is an advisor for Newlimit, Alnylam Pharmaceuticals, and Chroma Medicines. H.Z. receives research support from Chroma Medicines and owns stock in Ionis and Madrigal Pharmaceuticals. The remaining authors declare no competing interests.

Document is current

Any future updates will be listed below